nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Clinical applications of zolmitriptan (Zomig™, 311C90)
|
Lipton, Rb |
|
1997 |
17 |
18_suppl |
p. 53-59 |
artikel |
2 |
Introduction
|
Mathew, N |
|
1997 |
17 |
18_suppl |
p. 1-3 |
artikel |
3 |
Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig™, 311C90)
|
Rolan, P |
|
1997 |
17 |
18_suppl |
p. 21-27 |
artikel |
4 |
Pre-clinical pharmacology of zolmitriptan (Zomig™; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine
|
Martin, Gr |
|
1997 |
17 |
18_suppl |
p. 4-14 |
artikel |
5 |
The clinical pharmacokinetics of zolmitriptan
|
Dixon, R |
|
1997 |
17 |
18_suppl |
p. 15-20 |
artikel |
6 |
Tolerability profile of zolmitriptan (Zomig™ 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist
|
Edmeads, Jg |
|
1997 |
17 |
18_suppl |
p. 41-52 |
artikel |
7 |
Zolmitriptan (Zomig™, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: An overview of efficacy
|
Schoenen, J |
|
1997 |
17 |
18_suppl |
p. 28-40 |
artikel |